Over the past day in 85 regions of Russia, 6800 new cases of COVID-19 were detected (this is the minimum figure since April 29). According to the operational headquarters, 28.5% of new patients did not have clinical manifestations of coronavirus infection.

In the two days preceding this, 7113 and 7176 cases of coronavirus were recorded in the country. In total, in Russia, the diagnosis of COVID-19 was confirmed in 620,794 people.

From the beginning of the epidemic in Russia, 384 152 people (61.9%) recovered, including 8988 in the last day. From the complications that developed against the background of coronavirus infection and concomitant diseases, 8781 patients (1.41%) died. 176 people died per day.

Most new cases were recorded in Moscow (813), Moscow Region (390), Khanty-Mansi Autonomous Okrug (295), St. Petersburg (223), and Nizhny Novgorod and Irkutsk Regions (210 each).

According to Rospotrebnadzor, over 18.4 million tests for coronavirus have been carried out in the country over the entire period. 302.5 thousand people remain under medical supervision.

    Russian medicines and vaccines

    The other day, the Ministry of Health of Russia officially registered the drug “Arelivir”, intended for the treatment of COVID-19. According to the State Register of Medicines, this medicine is an analogue of the drug “Favipiravir” and will be available in tablet form. It is noted that the use of "Arelivir" is possible only in a hospital setting.

    “The results of clinical trials are known: in 90% of cases, the drug proved to be as effective as possible. In 70% of patients, after four days of taking the drug, coronavirus was almost completely absent in the body, ”Dmitry Zemskov, executive director of the biochemical manufacturing company, quotes TASS.

    According to him, clinical trials took place in hospitals in Mordovia, St. Petersburg and Moscow. As previously noted by the chief urologist of the Ministry of Health, academician Dmitry Pushkar, who is responsible for the implementation of the protocol for drug research in Russia, the treatment of patients with COVID-19 will not exceed seven days on average.

    We add that at the end of May the Ministry of Health registered the first in Russia medicinal product against coronavirus infection COVID-19 under the name Avifavir. It is also an analogue of the Japanese drug Favipiravir.

    Domestic development was included in the seventh version of temporary guidelines for the prevention and treatment of COVID-19. Avifavir has become one of the 15 possible drugs for treating coronavirus infection in adults. At the same time, the head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev during a meeting with Vladimir Putin reported that the drug would be provided free of charge in Russia as part of the compulsory medical insurance.

    The day before, Russia's chief sanitary doctor Anna Popova said that the distribution coefficient of COVID-19 throughout the country over the past two weeks did not exceed one, and at the moment it fell below 0.9.

    “The epidemic situation in the country is stabilizing. If in the middle - in the second half of March, the average daily growth rate was about 30%, on May 10 it was about 7%, today it is 1.3%, ”said the head of Rospotrebnadzor.

    She also said that the first industrial batch of coronavirus vaccines in Russia is planned to be received in the fall.

    Earlier, Russian Minister of Health Mikhail Murashko emphasized that clinical trials of the COVID-19 vaccine are underway as usual - the first phase should be completed within the next month.

    Currently, research is being carried out by specialists from the Ministry of Defense and the Gamalei Research Center. Volunteers under medical supervision at the Burdenko hospital told about their health.

    “As the vaccine was given to me, I didn’t even feel like an ordinary injection in the shoulder. There are no symptoms - the temperature is normal, 36.6. Even my head does not hurt, ”said volunteer Sergey.

    Another participant in the vaccine trials, Nikolai, confirmed that he did not feel any changes in well-being. “It was expected that the pressure would rise, the temperature, but there was nothing like that,” he said.

    Another volunteer, Yuri, also said that the vaccine did not affect his well-being.

    • AGN "Moscow"

    Population immunity in Moscow

    Moscow remains the leader in the country in the total number of detected cases of COVID-19 (218 604 for the entire time), but the number of new cases is gradually decreasing. 70 719 cases (32.4%) remain active, more than 144 thousand patients recovered, 3,694 people died.

    Moscow authorities said that residents of the city continue to form population immunity. According to the estimates of the deputy mayor for social development Anastasia Rakova, we are talking about 20% of the capital's inhabitants. According to her, the third stage of the study was conducted from June 5 to June 18. About 90 thousand people participated in antibody testing.

    The mayor of the capital, Sergei Sobyanin, broadcast on Rossiya 24, reported a reduction in the load on the city’s medical network due to a decrease in the number of patients. According to him, the existing "indicators provide a voluminous picture that cannot be manipulated."